Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study) by YRONDI, Antoine et al.
CLINICAL STUDY PROTOCOL
published: 24 July 2018
doi: 10.3389/fpsyt.2018.00326
Frontiers in Psychiatry | www.frontiersin.org 1 July 2018 | Volume 9 | Article 326
Edited by:
Renerio Fraguas,
Universidade de São Paulo, Brazil
Reviewed by:
Felice Iasevoli,
Università degli Studi di Napoli
Federico II, Italy
Douglas Watt,
School of Medicine, Boston University,
United States
Stephen Kent,
La Trobe University, Australia
Fulvio D′Acquisto,







This article was submitted to
Mood and Anxiety Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 11 April 2018
Accepted: 29 June 2018
Published: 24 July 2018
Citation:
Yrondi A, Aouizerate B, El-Hage W,
Moliere F, Thalamas C, Delcourt N,
Sporer M, Taib S, Schmitt L, Arlicot N,
Meligne D, Sommet A, Salabert AS,
Guillaume S, Courtet P, Galtier F,
Mariano-Goulart D, Champfleur NMD,
Bars EL, Desmidt T, Lemaire M,
Camus V, Santiago-Ribeiro MJ,
Cottier JP, Fernandez P, Meyer M,
Dousset V, Doumy O, Delhaye D,
Capuron L, Leboyer M, Haffen E,
Péran P, Payoux P and Arbus C
(2018) Assessment of Translocator
Protein Density, as Marker of
Neuroinflammation, in Major
Depressive Disorder: A Pilot,
Multicenter, Comparative, Controlled,
Brain PET Study (INFLADEP Study).
Front. Psychiatry 9:326.
doi: 10.3389/fpsyt.2018.00326
Assessment of Translocator Protein
Density, as Marker of
Neuroinflammation, in Major
Depressive Disorder: A Pilot,
Multicenter, Comparative, Controlled,
Brain PET Study (INFLADEP Study)
Antoine Yrondi 1*, Bruno Aouizerate 2, Wissam El-Hage 3, Fanny Moliere 4, Claire Thalamas 5,
Nicolas Delcourt 6, Marie Sporer 7, Simon Taib 7, Laurent Schmitt 7, Nicolas Arlicot 8,9,10,
Deborah Meligne 11, Agnes Sommet 5,12, Anne S. Salabert 13,14, Sebastien Guillaume 4,15,
Philippe Courtet 4,15, Florence Galtier 16, Denis Mariano-Goulart 17,18,
Nicolas Menjot De Champfleur 19,20,21,22, Emmanuelle Le Bars 19,20, Thomas Desmidt 23,
Mathieu Lemaire 23, Vincent Camus 23, Maria J. Santiago-Ribeiro 9,10,24, Jean P. Cottier 9,25,
Philippe Fernandez 26,27, Marie Meyer 26,27, Vincent Dousset 28, Olivier Doumy 2,
Didier Delhaye 29, Lucile Capuron 30, Marion Leboyer 31,32, Emmanuel Haffen 33,
Patrice Péran 14, Pierre Payoux 13,14 and Christophe Arbus 1
1 Service de Psychiatrie et de Psychologie Médicale de l’Adulte, Centre Expert Dépression Résistante FondaMental, CHRU 
de Toulouse, Hôpital Purpan, ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France,
2 Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, UMR
INRA 1286, NutriNeuro, Université de Bordeaux, Bordeaux, France, 3CHRU de Tours, Centre Expert Dépression Résistante
FondaMental, Inserm U1253 iBrain, Inserm CIC 1415, Tours, France, 4Department of Emergency Psychiatry and Postacute
Care, Lapeyronie Hospital, CHU Montpellier, Expert Center for Resistant Depression, Fondation Fondamental, Montpellier,
France, 5CIC 1436, Service de Pharmacologie Clinique, CHU de Toulouse, INSERM, Université de Toulouse, UPS, Toulouse,
France, 6Centre Anti Poison CHU Toulouse Purpan, ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm,
UPS, Toulouse, France, 7 Service de Psychiatrie et de Psychologie Médicale de l’Adulte, Centre Expert Dépression
Résistante FondaMental, CHRU de Toulouse, Hôpital Purpan, Toulouse, France, 8CHRU de Tours, Unité de Radiopharmacie,
Tours, France, 9UMR 1253, iBrain, Université de Tours, Inserm, Tours, France, 10 INSERM CIC 1415, University Hospital,
Tours, France, 11 Institut des handicaps des Handicaps Neurologiques, Psychiatriques et Sensoriels, FHU HoPeS, CHU
Toulouse, France, 12Unité de Soutien Méthodologique à la Recherche Clinique (USMR), CHU de Toulouse, Toulouse, France,
13Departement de Médecine Nucléaire, CHU Toulouse, Toulouse, France, 14 ToNIC, Toulouse NeuroImaging Center,
Université de Toulouse, Inserm, UPS, Toulouse, France, 15 INSERM U1061, Université de Montpellier, Montpellier, France,
16Centre Hospitalier Régional Universitaire Montpellier, Montpellier, France, 17 PhyMedExp, Université de  Montpellier,
INSERM U1046, CNRS UMR 9214, Montpellier, France, 18Département de Médecine Nucléaire, CHU de Montpellier,
Montpellier, France, 19Département de Neuroradiologie, Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de
Montpellier, Montpellier, France, 20 Institut d’Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, Centre Hospitalier
Régional Universitaire de Montpellier, Montpellier, France, 21 Laboratoire Charles Coulomb, CNRS UMR 5221, Université de
Montpellier, Montpellier, France, 22Département d’Imagerie Médicale, Centre Hospitalier Universitaire Caremeau, Nîmes,
France, 23CHRU de Tours, INSERM U1253, Université François Rabelais de Tours, Tours, France, 24 Service de Médecine
Nucléaire, CHRU Tours, Tours, France, 25 Service de Neuro radiologie, CHRU Tours, Tours, France, 26Departement de
Médecine Nucléaire, Hopital Pellegrin, Bordeaux, France, 27 Institut de Neurosciences Cognitives et Intégratives d’Aquitaine
(UMR-5287), Université de Bordeaux, Bordeaux, France, 28CHU Bordeaux Neurocentre Magendie, INSERM U1215,
Université de Bordeaux, Bordeaux, France, 29 Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression
Résistante FondaMental, CH Charles Perrens, Bordeaux, France, 30 INRA, Nutrition and Integrative Neurobiology
(NutriNeuro), UMR 1286, University of Bordeaux, Bordeaux, France, 31 Pôle de Psychiatrie des Hôpitaux Universitaires,
Centre Expert Dépression Résistante FondaMental, Hôpital Henri Mondor-Albert Chenevier, AP-HP, Créteil, France,
32 INSERM U955, Translational Psychiatry, Paris-Est University, Créteil, France, 33Department of Clinical Psychiatry,Clinical
Investigation Center 1431-INSERM, EA 481 Neurosciences, University of Bourgogne Franche-Comté, University Hospital of
Besancon and FondaMental Foundation, Créteil, France
Yrondi et al. Brain Neuroinflammation in Major Depressive Disorder
Background: Major depressive disorder (MDD) is a serious public health problem with
high lifetime prevalence (4.4–20%) in the general population. The monoamine hypothesis
is the most widespread etiological theory of MDD. Also, recent scientific data has
emphasized the importance of immuno-inflammatory pathways in the pathophysiology of
MDD. The lack of data on the magnitude of brain neuroinflammation in MDD is the main
limitation of this inflammatory hypothesis. Our team has previously demonstrated the
relevance of [18F] DPA-714 as a neuroinflammation biomarker in humans. We formulated
the following hypotheses for the current study: (i) Neuroinflammation in MDD can be
measured by [18F] DPA-714; (ii) its levels are associated with clinical severity; (iii) it
is accompanied by anatomical and functional alterations within the frontal-subcortical
circuits; (iv) it is a marker of treatment resistance.
Methods : Depressed patients will be recruited throughout 4 centers (Bordeaux,
Montpellier, Tours, and Toulouse) of the French network from 13 expert centers for
resistant depression. The patient population will be divided into 3 groups: (i) experimental
group—patients with current MDD (n = 20), (ii) remitted depressed group—patients in
remission but still being treated (n = 20); and, (iii) control group without any history of
MDD (n = 20). The primary objective will be to compare PET data (i.e., distribution
pattern of neuroinflammation) between the currently depressed group and the control
group. Secondary objectives will be to: (i) compare neuroinflammation across groups
(currently depressed group vs. remitted depressed group vs. control group); (ii) correlate
neuroinflammation with clinical severity across groups; (iii) correlate neuroinflammation
with MRI parameters for structural and functional integrity across groups; (iv) correlate
neuroinflammation and peripheral markers of inflammation across groups.
Discussion: This study will assess the effects of antidepressants on neuroinflammation
as well as its role in the treatment response. It will contribute to clarify the putative
relationships between neuroinflammation quantified by brain neuroimaging techniques
and peripheral markers of inflammation. Lastly, it is expected to open innovative
and promising therapeutic perspectives based on anti-inflammatory strategies for the
management of treatment-resistant forms of MDD commonly seen in clinical practice.
Clinical trial registration (reference: NCT03314155):
https://www.clinicaltrials.gov/ct2/show/NCT03314155?term=neuroinflammation&
cond=depression&cntry=FR&rank=1
Keywords: depressive disorder, depression, neuroinflammation, inflammation, TSPO, DPA-714, cytokines
INTRODUCTION
Major depressive disorder (MDD) is a serious public health
problem (1) with high lifetime prevalence (4.4-20%) in the
general population (2). Impairment of quality of life is
comparable to chronic diseases such as low back pain, high blood
Abbreviations: [18F]DPA-714, N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-
dimethylpyrazolo[1,5-α]pyrimidin-3-yl)acetamide fluoro 18; BAS, Brief Scale for
Anxiety; BBB, Blood-Brain Barrier; CERRP, Centre d′Etudes et de Recherches
sur les RadioPharmaceutiques; CRP, C Reactive Protein; CSSRS, Columbia
Suicide Severity Rating Scale; DSM, Diagnostic and Statistical Manual of Mental
Disorders; ECT, Electroconvulsive therapy; MDD, Major Depressive Disorder;
IL, Interleukin; MAOI, Monoamine oxidase inhibitor; SSRI, Serotonin Reuptake
Inhibitor; MADRS, Montgomery and Asberg Depression Scale; mSv, Milli Sievert;
TNF, Tumor Necrosis Factor; TSPO, Translocation protein.
pressure, or cancer (3, 4). MDD is considered a “deactivation
of psychosocial function” (5). It usually appears as part of a
complex picture of comorbidities that are most often not or
hardly managed since they may not be recognized (6). Standard
therapeutic strategies often fail in up to one-third of cases
in everyday clinical practice (7). The definition of treatment-
resistant depression varies in the literature. Nevertheless, it
is characterized by the absence of significant symptomatic
remission after two successive attempts with antidepressants of
different pharmacological classes, well-conducted in terms of
dosage and duration, whilst ensuring quality observation (at least
80% of treatments made during the period under consideration)
(8, 9).
The monoamine hypothesis is the most widespread
aetiological theory of MDD (10, 11). Hence, all available
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antidepressants primarily act by increasing monoamine
neurotransmission (serotonin, dopamine, and noradrenaline)
(12). Consequently, hypofunction of the brain monoamine
systems is among the most critical neurochemical mechanisms
implied in MDD.
Recent scientific data has emphasized the importance of
immuno-inflammatory pathways in the pathophysiology of
MDD based on 4 main observations. First, a high prevalence
of depressive symptoms is observed in chronically ill patients
treated with the pro-inflammatory cytokine interferon-alpha (13,
14). Second, there is a high frequency of depressive symptoms
in patients suffering from autoimmune or chronic inflammatory
diseases (15–18). Third, a significant association has been found
between an increase in the inflammatory marker CRP and the
subsequent onset of depressive symptoms (19–22). Fourth, there
is an increase in circulating cytokines, both at peripheral and
central levels, in depressed patients (23, 24). Amongst them,
TNFα and IL-6 are most often increased. The results concerning
IL-1β and IL-8 are more contradictory (23). These cytokines
in the central nervous system (CNS) appear to result from
microglia activation (25–27). Microglia activation is one of the
characteristics of neuroinflammation (28). This contributes to the
secretion of pro-inflammatory cytokines and nitric oxide (NO)
(29). Microglia also contributes to the resolution of inflammation
by releasing anti-inflammatory factors. This theory seems to
be part of a broader bio-psycho-social conceptual framework.
Indeed, it has largely been documented that exposure to stressful
life situations such as social aggression, traumatic events of life,
etc. known to increase the risk for the further development of
depressive episodes, have a significant impact on the functioning
of the Immune-Hypothalamo-pituitary-adrenal axis (30, 31). In
addition, epigenetic mechanisms are presumably implicated in
those functional alterations related to stress (31–33).
In parallel, neuroimaging data reveal that a wide range
of brain regions and networks may be involved in MDD,
reflecting the complexity and diversity of depressive states
(34). Relationships with the inflammation status have been
established. A negative correlation was found between plasma
CRP levels and the thickness of the right medial prefrontal cortex
in MDD. This negative association is secondary to enhanced
production of neurotoxic metabolites such as quinolinic acid
from the kynurenine pathway activated in inflammatory
conditions (35). Savitz et al. have also found a strong
relationship with the reduction in striatum volume in a
MDD sample. Furthermore, striatal volume was correlated
with several depression-related items primarily referring to
“concentration difficulties,” “lassitude,” and “pessimism” (36).
Numerous neuroimaging studies (37–41) in MDD have found
functional abnormalities of those neuronal systems in MDD in
either resting conditions or during specific challenging tasks.
Also, peripheral inflammation is associated with the anatomical
and functional changes that occur during MDD. Corticostriatal
functional connectivity is decreased in depressed patients, which
is negatively correlated with plasma levels of CRP and IL-6 (42).
The lack of data on the magnitude of brain
neuroinflammation in MDD is the main limitation of
the inflammatory hypothesis of MDD. Positron emission
tomography (PET) imaging may provide a better understanding
of the pathophysiology of MDD involving cases of CNS brain
inflammation. The development of new radiotracers used in
PET helps us to explore and quantify neuroinflammation in
depressed patients. Many of these radiotracers specifically have
as target the translocation protein (TSPO). The TSPO is an
18 kDa protein located in the outer mitochondrial membrane
of microglia cells. Its density is measured by its distribution
volume, which was shown to be increased when microglia is
activated thereby contributing to consider changes in TSPO
expression as a relevant biomarker for brain neuroinflammation
(43). An initial study conducted by Hannestad et al. (44) using
a carbonaceous radiotracer of TSPO (11-N-(2-methoxybenzyl)-
N-(4-phenoxypyridin-3-yl)acetamide-[11C] PBR28) found no
significant increase in TSPO in acute-phase MDD patients
(n = 10). However, this study was conducted in a small group of
patients who were clinically heterogeneous in terms of disease
severity. Setiawan et al. recently reported a significant increase
in the TSPO distribution volume in 20 patients with MDD in
the right and left prefrontal cortex, anterior cingulate gyrus,
and insula using a fluorinated marker ([18F] FEPPA) (45). To
our knowledge, these are the first data to suggest that MDD
is characterized by neuroinflammation found in specific brain
regions implicated in the cognitive and emotional processing of
environmental stimuli (45).
Our team recently demonstrated the relevance of [18F]
DPA-714 as a neuroinflammation biomarker in humans with
various neurological diseases (46). The [18F] DPA-714 and
[18F] FEPPA molecules are two second radiotracers targeting
TSPO (overexpressed microglial receptor with inflammation).
The [18F]DPA-714 tracer has been studied extensively in
humans and also in preclinical models (46–49). This tracer was
also selected by the European consortium InMind (Imaging
of Neuroinflammation in Neurodegenerative Diseases−7th
Framework Programme of the EU—www.uni-muenster.de/
InMind) as the gold standard for PET neuroinflammation
imaging with TSPO. Since [18F] DPA-714 appears to be the
currently preferred tracer for studying neuroinflammation in
PET, it will be used in this study.
The primary objective of this study is to compare the TSPO
distribution volume assessed in PET (DPA-714) between patients
with moderate-to-severe MDD (“currently depressed group”)
treated with antidepressants considered as ineffective (and before
a new treatment strategy is initiated as recommended) and
normal healthy subjects without any antidepressant treatment
(“control group”).
The secondary objectives are to: (i) compare the TSPO
distribution volume assessed by PET among the currently
depressed patients, those in clinical remission but still being
treated with antidepressants (“remitted depressed group”)
and normal controls; (ii) correlate the severity of depressive
symptoms, suicidal risk, and central neuroinflammation intensity
evaluated by PET in the currently depressed group; (iii) measure
the correlation between the distribution volume of PET-assessed
TSPO and a series of structural (microstructural integrity,
cortical thickness, intracerebral iron content) and functional
(connectivity force of the default-mode network) MRI markers
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in the three subject groups; (iv) measure the correlation between
the distribution volume of PET-assessed TSPO and the plasma
concentrations of peripheral inflammatory markers in the three
subject groups.
We formulated the following hypotheses: (i)
Neuroinflammation in MDD can be measured by [18F]
DPA-714; (ii) its levels are associated with clinical severity; (iii) it
is accompanied by anatomical and functional alterations within
the frontal-subcortical circuits that are highly involved in MDD;
(iv) it is a marker of treatment resistance. If these hypotheses
are confirmed, then this study will enhance our understanding
of the role of these neuroinflammatory processes in MDD. This
breakthrough could have a significant long-term therapeutic
impact by developing more specific antidepressant drugs with




Our study will compare data collected in patients with moderate
to severe MDD (“currently depressed group”, n = 20) treated
unsuccessfully with classical antidepressants (SSRIs, SNRIs)
before the initiation of a new antidepressant treatment according
to good practice recommendations, with those included in two
other study groups, comprising:
- non-depressed healthy volunteers (“control group”, n = 20),
which enables us to control both the depression factor
and the treatment factor for the characterization of
neuroinflammation. They will be matched on age and
gender to the experimental group of currently depressed
patients;
- depressed patients reaching clinical remission (“remitted
depressed group”, n = 20) and still being treated with
antidepressants, which allows us to control the depression
factor. We hypothesize that the presence of an effective
antidepressant treatment will contribute to demonstrate a
significant decrease in neuroinflammation in those depressed
patients. This groupwill bematched to the currently depressed
group according to the class of antidepressant treatments
(SSRIs, SNRIs), as well as age and gender.
Eligibility Criteria
The following inclusion criteria will be applied to all study
groups: (1) men and women aged 25 to 55 years, (2) affiliated
to a Social Security scheme, (3) able to understand the given
instructions and information about the study design, and
(4) have provided written informed consent. The currently
depressed group will include patients: (1) meeting the DSM-5
criteria ofMDDdiagnosis, (2) experiencing significant depressive
symptoms (as indicated by a score > 20 on the Montgomery
and Asberg Depression Rating Scale, MADRS), (3) receiving an
ineffective antidepressant treatment (a well-conducted treatment
at an appropriate dosage for a minimum of 6 weeks), and
(4) showing plasma antidepressant levels within the therapeutic
range after at least 1 additional week of antidepressant treatment
with unchanged dosage. The remitted depressed group will
comprise patients: (1) meeting the DSM-5 criteria of MDD
diagnosis, (2) achieving remission for at least 8 consecutive
weeks according to the standard DSM-5 criteria (as indicated
by a MADRS score < 10), and (3) receiving antidepressant
medications at a stable dosage for 1 week or more. The control
group will include normal healthy subjects free from any current
or past psychiatric conditions and without peripheral signs of
inflammation (as indicated by circulating concentrations of hs-
CRP < 5 mg/L).
Patients with any of the following conditions are not eligible
for both the currently depressed and remitted depressed groups:
(1) woman who is pregnant (test at enrolment), parturient, or
lactating, (2) persons deprived of their liberty by judicial or
administrative decision, (3) persons unable to express consent,
(4) subjects with an identified neurodegenerative condition or
a psychiatric pathology other than MDD (bipolar disorder,
chronic psychotic disorder, addictive disorder except for nicotine,
obsessive-compulsive disorder, post-traumatic stress disorder),
(5) subjects with a history of stroke, (6) subjects with an acute
infectious pathology, or chronic or acute inflammatory diseases,
(7) subjects with a history of autoimmune diseases, (8) subjects
receiving long-term anti-inflammatory and immunosuppressive
therapy, (9) subjects with antipsychotic treatment in the last 3
weeks prior to enrolment, (10) subjects with a prescription of
diazepam, midazolam, chlordiazepoxide in the last week prior
to enrolment, (11) subjects with contraindications to MRI or
PET imaging, (12) subjects who refuse to be informed of an
abnormality detected during MRI examination.
The exclusion criteria for the control group are: (1) a
significant history of psychiatric or somatic disorders, (2) a
current mental disorder, (3) an active suicidal risk, (4) an ongoing
psychotropic treatment.
Depressed patients will be recruited throughout 4 centers
(Bordeaux, Montpellier, Tours, and Toulouse) of the French
network from 13 expert centers for resistant depression (50).
The subjects of the control group will be included at clinical
investigation sites working locally in close collaboration with
each participating expert center.
Clinical Assessment
A psychometric assessment will be performed by trained and
independent psychiatrists to assess the following items.
• Depression severity will be assessed using the French version
of the MADRS (Montgomery and Asberg Depression Rating
Scale) (51), a hetero-evaluation scale for depression. It
is amongst the most widely used in everyday practice,
comprising 10 items. The total score ranges from 0 to 60.
Remission is considered to have been reached when the total
MADRS score is less than 10.
• Anxiety severity will be evaluated using the French version
of the BAS (Brief Scale for Anxiety) (52), a hetero-evaluation
questionnaire evaluating anxiety intensity comprising 10
items: 6 for general symptoms and 4 for psychological
symptoms. Each item is scored from 0 to 6 (53).
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• Suicidal ideation and behavior will be examined using the
French version of the C-SSRS (Columbia-Suicide Severity
Rating Scale) (54). It assesses suicidal ideation for a given
topic ranging from ‘wish to be dead’ to ‘active suicidal ideation
with specific plan and intent.’ There are 5 closed questions on
suicidal ideation, 6 questions on intensity, and 4 on suicidal
behavior.
PET Assessment
The 18F-DPA-714 and 18F-FEPPA molecules are two second
radiotracers that target TSPO (overexpressed microglial receptor
with inflammation) (55, 56). These two tracers cross the blood-
brain barrier (BBB) and have a good affinity for TSPO (57,
58). The 18F-DPA-714 tracer is metabolized rapidly and some
metabolites secondary to oxidation can cross the BBB in small
amounts (59). The FEPPA tracer is also metabolized but its
hydrophile metabolites do not cross the BBB (57). The amounts
of injected activity and the effective patient dose are comparable
between the two tracers (47, 60–62). The 18F-DPA-714 tracer
has been studied extensively in humans as well as in preclinical
models (51 references on Medline) (46–49). There is less
information on the use of FEPPA (14 references onMedline, only
8 clinical studies).
Articles on the FEPPA use in humans mention an acquisition
time of 125min, which is difficult to achieve with a large
number of subjects and is very uncomfortable for patients
who must be immobile during these 125min. For FEPPA,
the data analysis is performed on a kinetic model with two
compartments and arterial blood samples must be collected from
the patient to measure the input function of the radiotracer
(62). The main advantage of using 18F-DPA-714 is its acquisition
and analysis protocol. The radiotracer is injected (200MBq)
and then a 30-min acquisition is performed 1 h after the
injection. The analysis consists of calculating a standardized
uptake value (SUV). Some studies have shown that using this
semi-quantitative analysis method and using a reference region
results in less variability than studies using a kinetic model
(49). Since 18F-DPA-714 appears to be the preferred tracer for
studying neuroinflammation on PET, it will be used in this
study.
In addition, there is known a genetic polymorphism for TSPO.
This polymorphism determines the tracer′s affinity for TSPO,
with some persons having high affinity sites, mixed affinity sites
or lower affinity sites. The two radiotracers (18F-DPA-714 and
18F-FEPPA) are both impacted by this genetic polymorphisms
(63). For feasibility reasons, the TPSO genotype of subjects
cannot be an inclusion criterion; nevertheless, this parameter will
be taken into account during the data analysis as a covariate,
allowing us to weigh the PET imaging data based on whether the
individuals have high or low affinity sites.
Biological Markers
The involvement of certain pro-inflammatory cytokines in MDD
was highlighted in a meta-analysis by Dowlati et al. (64) and
a recent literature review by Miller et al. (23). In these two
articles, higher plasma concentrations of IL-6 and TNF-alpha
were found in theMDD group than in the control groups without
MDD.
The biological marker assessment will involve measuring
the concentration of peripheral inflammation markers that are
circulating cytokines including IL-6 and TNF-alpha, especially.
For each research site, samples will be taken at the Clinical
Investigation Center for all subjects.
Also, hs-CRP will be assayed on the pre-screening day as part
of the usual follow-up of patients and as part of the enrolment
visit for volunteers in the control group (exclusion criteria for
volunteers in the control group showing hs-CRP levels > 5
mg/L indicating a significant inflammatory state). All the blood
samples will be collected in the morning in order to limit the
impact of circadian rhythm on themeasurement of inflammatory
markers.
The samples will be stored by the Clinical Investigation
Centers associated with each expert center before being sent
to the hospital departments involved in the determination of
peripheral cytokine levels (IL-6 and TNF alpha) at the end of the
study.
Outcomes
The primary outcome will be the TSPO density assessed by the
volume of cerebral distribution of the tracer [18F]DPA-714 in the
currently depressed group vs. the control group.
The secondary outcomes will be: (1) the TSPO density
evaluated by the brain distribution volume of the [18F]DPA-714
tracer in the currently depressed vs. remitted depressed groups,
(2) the clinical severity assessed by the Montgomery and Asberg
Depression Scale—MADRS), BAS (Brief Scale for Anxiety), and
the Columbia-Suicide severity rating scale—CSSRS), (3) MRI
imaging: (i) structural (i.e., cortical thickness to quantify cortical
atrophy); (ii) diffusion (i.e., the mean diffusivity for measuring
microstructural integrity); (iii) T2∗ relaxometry (i.e., the R2∗
for measuring intracerebral iron content), and (iv) resting-
state functional MRI (i.e., default mode network connectivity
strength), (4) the concentrations of biological markers of
peripheral inflammation (i.e., hs-CRP, IL-6, TNF alpha).
Risk Benefit Balance
No direct individual benefit can be expected for subjects
participating in this study. The therapeutic modalities used in
these patients will not be altered by their participation in the
study or by the results. Strict compliance with the inclusion
and exclusion criteria will ensure there are no foreseeable risks
for persons participating in this study. The imaging modalities
used (MRI and PET) do not involve any foreseeable risk when
patients presenting a contraindication to one or other of these
examinations are not included according to the aforementioned
inclusion/exclusion criteria. The principal investigator must
constantly monitor, assess, and document risks and ensure that
they can be managed satisfactorily.
Experimental Procedures (Table 1)
Preselection
Patients in both the currently depressed and remitted depressed
groups will be preselected during their medical follow-up within
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Search for AE/SAE X X
1Clinical examination: discussion with doctor, MADRS, BAS, C-SSCR, MINI surveys.
2To measure CRP levels in healthy volunteers and biological markers (TNF-alpha, IL-6),
TSPO phenotype in all subjects, beta-HCG for women of childbearing age.
each participating research site. Investigators will inform the
patient and answer all questions about the purpose, nature of
constraints, foreseeable risks, and expected benefits of the present
research. They will also specify the rights of the patient regarding
research and will verify the eligibility criteria. A copy of the
Information/Consent form will then be given to the patient.
Healthy volunteers for the control group will be invited by phone
to participate into the study by a Clinical Investigation Centre
clinical research associate. A copy of the information leaflet will
be sent to them, giving them sufficient time to consider their
participation.
Enrolment Visit
After obtaining the subject′s consent, a clinical examination
will be performed to verify the eligibility criteria of the
potential study participants along with the collection of
psychiatric and somatic history, and current treatments. This
clinical examination will include MINI (Mini International
Neuropsychiatric Interview) (Appendix 5), which consists of a
short, structured clinical interview that allows investigators to
diagnose past and current psychiatric disorders according
to the DSM (65), which is an exclusion criterion for
subjects in the control group. This visit will also involve
conducting psychometric assessments (MADRS, BAS,
C-SSCR).
A blood sample will be taken to measure hs-CRP levels
(inclusion criterion for the control group). This sample will also
be used to measure IL-6 and TNF-alpha if the subject is included
in the study. All the samples will be taken in the morning
to take into consideration, as much as possible, the effects
of circadian rhythm on circulating inflammatory biomarkers.
Thereafter, an appointment will be scheduled for the assessment
visit depending on the availability of the subject and the different
technical platforms, at 7 ± 5 days following the inclusion
visit.
Assessment Visit
A PET scan ([18F]DPA-714) and a multimodal MRI scan will
be performed. The subjects will be taken to an imaging unit
for an MRI examination of around 40min duration. As a safety
measure, theMRI technician will carry out the usual safety checks
needed for this type of investigation. The subjects will then be
placed on a table, with their head positioned to enable brain
imaging to be carried out. After placing the subject′s head in the
support inside the MRI scanner, the scanning sequences will be
carried out. The subjects will be able to talk to the operator at all
times by intercom. Subjects must in general keep still during the
MRI sequences. If an abnormality is discovered, the investigator
will inform the patient during a follow-up visit.
Statistical Analyses
The Clinical Investigation Center in Toulouse contributed to
the design of the study. The latter also provides methodological
support to the project.
Study Sample Calculation
The main objective is to compare the central neuroinflammation
measured by the TSPO distribution volume assessed by PET
among both currently depressed and control groups. To our
knowledge, this is the first study using the [18F] DPA-714 as
biomarkers of neuroinflammation in depression with this type
of study design. So, we cannot calculate the power of the study.
However, few studies of this type are available in the scientific
literature. There are studies using othermarkers of inflammation,
such as [18-F]FEPPA (45). In the absence of sufficient literature
data on which to base the calculation, a population of 20
patients per group seems appropriate considering the size of
neuroimaging studies in the literature. In addition, 20 patients
per group will allow us demonstrating, with a power of 80%,
a statistically significant difference in the distribution volume
between patients with a major depressive episode and controls,
in the event the measured volume is similar according to the
markers (based on data from the Setiawan et al. study measuring
a volume of distribution of 12.3 vs. 9.3 ml/cm3 in the medial
prefrontal cortex).
Analysis of PET Imaging Data
To evaluate the brain kinetics of [18F] DPA-714, PET images
will be co-recorded on the MNI atlas with PMOD R© software. To
construct time-activity curves of [18F] DPA-714, the PET images
will be segmented into 13 regions of interest (ROI): precuneus,
anterior cingulum, posterior, frontal, temporal, parietal, occipital
cingulum, hippocampus, semi-oval centrum, anterior putamen,
posterior putamen, caudate nucleus, and intersections, as defined
in the MNI-AAL atlas. The binding potential (BP) is the ratio of
Bmax (receptor density) to KD (dissociation constant): BP= Bmax
/ KD shall be calculated. Additionally, the distribution volume
ratio (DVR) will be estimated from the region of interest and
a reference region using, for example, Logan graphical analysis
(66) with the cerebellum as reference region for the images
obtained between 0 and 90min (46). In this study, the DVR will
be calculated as the slope of the linear part of the Logan analysis
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using PMOD software. We will calculate the BP for the 13 ROIs
mentioned above, as well as for the entire brain.
For the primary hypothesis, PET data will be analyzed by
multivariate ANOVA with TSPO Volume in the 13 ROIs as the
dependent variables and diagnosis and genotype as fixed factors.
Main effects will be considered significant at the conventional
P ≤ 0.05. Effects in each region, will be analyzed by univariate
ANOVA.
As a secondary analysis, a MANOVA including every
brain region sampled (including all cortical and subcortical
regions) will be performed to assess the effect of diagnosis
on TSPO Volume. A partial correlation will be used in a
secondary analysis to quantitate the relationship between
TSPO Volume in the primary regions of interest and
severity of symptoms of MDD measured by total MADRS
score.
Analysis of MRI Data
For structural MRI analysis, image processing will be performed
using FSL 4.1 (FMRIB Software Library; www.fmrib.ox.ac.uk/
fsl/) and an in-house software developed in Matlab (version 6.5,
The MathWorks), with procedures similar to those described
earlier (67–70). Using T1 anatomical image, we will identify
and segment hippocampi and amygdala. Concerning diffusion
weighted imaging, a diffusion tensor imaging model will be
fit at each voxel, generating mean diffusivity (MD) maps.
The MD maps were then registered to brain-extracted whole-
brain volumes from T1-weighted images using a full affine
(correlation ratio cost function) alignment with nearest-neighbor
resampling. As a result of this processing, the MD maps were
corrected for head movements, and shared an identical reference
space with the anatomical T1-weighted volumes. For standard
volumetric analysis, we will extract volume values from each
segmented structure and divided this value by the total intra-
cranial volume (TIV) to normalize for participant′s brain size.
For each subject, the region of interest segmentation results,
coregistered MD were all superimposed onto the original T1-
weighted volume. The segmented structures defined the binary
masks, where the mean values of MD will be calculated for each
individual.
For functional MRI analysis, image processing will be
performed using SPM12 (https://www.nitrc.org/projects/
spm), CONN toolbox (https://www.nitrc.org/projects/conn)
and an in-house software developed in Matlab (version 6.5,
The MathWorks). Individual correlation maps between the
defined regions (hippocampus, amygdala, anterior cingulate
gyrus, frontal cortex—these areas of interest are anatomical
zones defined in known and classical stereotactic spaces in
neuroimaging) and the whole brain will be determined. The
coordinates of the regions are identical for each subject because
the images are in an identical (MNI) space. The correlation
indices will be transformed into normally distributed variables
using the Fisher transformation. These maps will then be used to
carry out a t-test, corrected for multiple comparisons, between
the maps of different groups. This will allow us to determine the
intensity and extent of synchronous activity in the cerebral zones
functionally connected to the hippocampus, the amygdala, and
the prefrontal cortex.
Analysis of all Data
PET and MRI imaging, clinical symptomatology and biological
markers. PET and MRI images will be co-recorded using a
method previously used by our team (71) [e.g., (71)] so that
the maps of all multimodal markers have the spatial consistency
needed for their statistical comparison. Firstly, for each marker
map, we will perform t-tests to compare the groups with each
other (SPSS 25.0). This will allow us to quantify the structural,
functional and inflammatory alterations that characterize each
group (i.e., treatment-resistant MDD vs. control, responsive
MDD vs. control, treatment-resistant MDD vs. responsive
MDD). Secondly, we will verify that there is no spatial collocation
between the atrophy marker (MRI) and the inflammation
marker (DPA714 -PET) that can induce a different interpretation
of PET results. Finally, we will correlate the inflammation
marker maps with the structural and functional marker maps
generated with MRI. This will allow us to understand whether
neuroinflammation is linked to brain changes (e.g., iron deposits,
functional alteration).
To study the correlation between the severity of depressive
symptoms, suicide risk and the intensity of neuroinflammation,
graphic representations will be made to observe the distribution
of these data in the two groups concerned. The Pearson
correlation coefficient will be calculated in each instance. The
same analysis strategy will be used to measure the correlation
between plasma concentrations of biological markers of
peripheral inflammation and the intensity of neuroinflammation
in the three study groups.
Ethics
This protocol has been approved by an independent national
research ethics committee (CPP Île-de-France 6; RC31/16/8918
CPP/41-17). The protocol was also registered in the clinical trial
database (NCT03314155).
DISCUSSION
MDD is a highly prevalent disorder associated with a
considerable loss of quality of life, increased mortality rates,
and substantial economic costs. Because of a lack of knowledge
about this disease, many patients remain untreated. Among
patients given adequatemedication, only 35%will achieve clinical
remission. Furthermore, the probability of recurrences increases
with the number of previous depressive episodes (7, 72, 73).
Greater knowledge about the pathophysiology of MDD seems
therefore necessary.
The inflammatory approach is an extension of the early
monoamine theory of MDD, which has remained the only
explanatory model for many years (74). Indeed, in inflammatory
conditions, cytokines regulate monoamine neurotransmitters,
notably serotonin. The most relevant mechanism involves
activation of the inducible enzyme indoleamine 2,3 dioxygenase
(IDO) which degrades tryptophan (TRP) into Kynurenine
(KYN). Yet, TRP is a precursor of serotonin, meaning serotonin
levels will be decreased (23). Similarly, inflammation is
associated with lowered dopamine function (75). In addition,
the pro-inflammatory cytokines appear to stimulate the
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hypothalamic-pituitary-adrenal axis, as one of the major stress-
responsive biological system (76, 77). There is a cascade reaction
at the hypothalamic and pituitary levels with an elevation in
CRH and ACTH concentrations. At the adrenal level, there
is an increase in cortisol synthesis. However, high plasma
cortisol levels fail to decrease efficiently the activation of the
transcription factor NF-kB levels controlling the expression of
pro-inflammatory genes in the CNS (23). These data seem to fit
into a larger framework for the pathophysiological knowledge
of MDD. Indeed, the immune-mediated mechanisms occupy
a pivotal position among the neurobiological determinants of
MDD. Inflammation has extensively been found to generate
serious deficits in synaptic plasticity as well as profound
disturbances of neurotransmitter systems, underlying the
cognitive and behavioral symptoms of MDD. Indeed, preclinical
models of stress-induced depression have shown how peripheral
and central immune components can initiate and propagate
inflammatory signals in the brain. Microglia is the primary
mediator of these neuroinflammatory responses and, when
exposed to stress, exhibit profoundmorphological and functional
alterations that play a key role in the development of anxious and
depressive behaviors. In addition, neuroplasticity and behavioral
deficits occur when microglia is distanced from homeostatic
processes and engaged toward maladaptation in response to
stress (78). Nevertheless, it is important to emphasize the fact
that those abnormal inflammatory processes seem to take
place only a subset of depressed patients (78, 79), as attested
by high peripheral levels of the inflammatory marker CRP
above 3 mg/L found only in 16% of a large sample of depressed
patients (79), leading to consider MDD not as the sole result
of an impaired immune function. Despite these considerations,
the findings supporting the inflammatory hypothesis of
MDD could open up significant opportunities for medical
management of those depressed patients with inflammatory
profile.
Altogether, these findings should open up new opportunities
for MDDmedical management. Twometa-analyses (80, 81) have
highlighted the anti-inflammatory role of serotonin reuptake
inhibitors (SSRIs). The meta-analysis by Hannestad et al. (81)
has found decreased IL6 and IL-1β serum concentrations
in successfully treated patients with MDD, although these
data remain contradictory. In contrast, several studies have
documented that depressed patients having high baseline
peripheral inflammatory cytokines (IL-6, TNF-alpha) and gene
expression fails to respond adequately to SSRIs (82–84).
Therefore, the use of anti-inflammatory molecules such as anti-
TNFα is a new research avenue for treating MDD. Reason and
colleagues have shown infliximab to be effective for treating
MDD in depressed patients with a CRP greater than 5 mg/L (85).
In their meta-analysis, Fond et al. (80) and Abbasi et al. (86)
suggested combining a COX2 inhibitor to block the production
of pro-inflammatory prostaglandins with an antidepressant for
the treatment of MDD. Relationships were found between an
improvement in depressive symptoms and decreasing circulating
levels of IL-6. In addition, brain stimulation techniques
such as electroconvulsive therapy currently proposed for the
management of resistant forms of MDD appear to modulate the
immunoinflammatory cascade (87).
In this context, the development of biomarkers to differentiate
MDD from treatment-resistant MDD is a major challenge.
Demonstrating different clinical clusters in MDD through
neuroinflammation could lead to more personalized patient
care. Some symptoms of depression such as anhedonia, loss
of interest, and psychomotor retardation are associated with
biomarkers of peripheral inflammation (88–90). However, this
data mainly refers to peripheral markers of inflammation.
Will we find this association with neuroinflammation in our
study? In a previous study, Setiawan et al. showed that the
highest TSPO distribution volume occurred in MDD patients
with the most severe depressive symptoms. But they did not
demonstrate any relationship between neuroinflammation and
peripheral markers of inflammation. Importantly, there is no
available data on the TSPO distribution volume in depressed
patients in clinical remission (45). Moreover, to our knowledge,
although relationships with active suicidal ideation was recently
established (91), there is no scientific study supporting a link
between certain symptoms of MDD such as anhedonia, loss of
interest and psychomotor retardation with neuroinflammation,
despite available data on peripheral inflammation markers.
We will therefore try to highlight at the level of the CNS what
existing scientific data currently finds at the peripheral level to
attempt to show a significant correlation between peripheral and
central modifications in MDD.
CONCLUSION
Our study′s first objective is to investigate the link between
neuroinflammation and clinical severity, as shown earlier by
Setiawan (65), and also to target the relationships with certain
clinical dimensions such as anhedonia, aboulia, etc. However,
the current research aims to assess the effects of antidepressants
on neuroinflammation as well as its role in the treatment
response. It will help to clarify the putative relationships
between neuroinflammation quantified by brain neuroimaging
techniques and peripheral markers of inflammation. Finally, it
opens innovative and promising therapeutic avenues based on
anti-inflammatory strategies for the management of treatment-
resistant forms of MDDwhich are frequently observed in clinical
practice. This translational approach is expected to markedly
reduce the deleterious impact of MDD on overall functioning,
quality of life and economic costs due to the disease.
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